The purpose of this study is to determine whether HMG-CoA reductase inhibitor, atorvastatin attenuates inflammation in atherosclerotic plaques detected by 18F-fluorodeoxyglucose(FDG) PET.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
30
Subjects are advised to keep dietary habits according to the National Cholesterol Education Program (NCEP) from the run-in period throughout the study. The subjects are administered with 10mg/day for 3 months, if LDL-cholesterol levels does not decrease less than 80mg/dl, the dose is increased up to 20mg/day. If LDL-cholesterol levels decrease less than 60mg/dl, the dose is decreased down to 5mg/day or less.
Subjects are advised to keep dietary habits according to the National Cholesterol Education Program (NCEP) from the run-in period throughout the study.
National Defense medical College
Tokotozawa, Saitama, Japan
RECRUITINGStandardized uptake value (SUV) of 18-FDG detected in carotid/aortic atherosclerotic plaques
Time frame: Baseline and 3 months after intervention
Flow-mediated vasodilation of brachial artery determined by ultrasonography
Time frame: Baseline and 3 months after intervention
Serum markers for inflammation such as high-sensitive CRP, IL-6 or soluble ICAM-1
Time frame: Baseline and 3 months after intervention
Serum and urine markers for anti- or pro-oxidant stress such as oxidized LDL or 8-Hydroxydeoxyguanosine
Time frame: Baseline and 3 months after intervention
Max-intima-media thickness (Max-IMT), Mean-IMT and plaque score determined by carotid artery ultrasonography
Time frame: Baseline and 3 months after intervention
Serum lipids such as total cholesterol, LDL-cholesterol, HDL-cholesterol, RLP-cholesterol and triglycerides
Time frame: Baseline and 3 months after intervention
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.